UAH Receives $3.67 Million for Alphavirus Research
The University of Alabama in Huntsville aims to develop new treatments for mosquito-borne viruses.
Updated on Oct. 31, 2026 in Diseases — General
Live Poll
Should federal research funding prioritize developing medical treatments for emerging viral threats?
The National Institutes of Health has awarded a $3.67 million research grant to the University of Alabama in Huntsville. Dr. Victor Ogungbe will lead a five-year project to develop therapeutics for alphaviruses, which are mosquito-borne diseases.
Why it matters
There are currently no vaccines or therapeutics approved for human use against alphaviruses. This research seeks to prevent neurological complications by protecting the brain from infection.
The NIH grant provides $3.67 million for a five-year study on small-molecule compounds that inhibit nsP2 protease activity. The project builds on preliminary findings where these compounds successfully inhibited viral replication in cell cultures and protected mice.
The players
University of Alabama in Huntsville
This is a public research university located in Huntsville, Alabama, that hosts advanced scientific and medical studies.
Dr. Victor Ogungbe
He is the lead researcher at the University of Alabama in Huntsville responsible for managing the five-year project.
National Institutes of Health
This is the primary federal agency of the United States government responsible for biomedical and public health research.
Professor Aarthi Narayanan
She is a professor at George Mason University in Fairfax, Virginia, and is collaborating on the alphavirus research project.
The details
The research team focuses on blocking the nonstructural protein 2 protease domain to stop alphavirus replication. Collaborating with George Mason University, researchers will utilize organ-on-a-chip models to assess blood-brain barrier permeability and viral levels.
Timeline
October 30, 2026: The University of Alabama in Huntsville announced the research project.
Five-year duration: The active term of the National Institutes of Health grant.
Health Landscape
This project represents a critical advancement in the pipeline for addressing emerging infectious diseases with limited medical interventions. It builds upon the established framework of the NIH-funded Small Molecule Drug Discovery program to bridge the gap between laboratory results and clinical viability.
While this research is in the early stages, it aims to establish a new pathway for potential medical treatments that could eventually protect the public from severe neurological complications. There is no immediate change to current medical treatment options or local clinical practices for residents.
The takeaway
This project aims to improve the potency of compounds through structure-activity relationship studies to preserve blood-brain barrier integrity. Local residents should monitor future updates as the team works to translate these findings into viable medical therapeutics.
Further reading
Learn more about ongoing research into Diseases — General at the university level.
Source note: This article includes information reported by News-Medical.
Live Poll
Should federal research funding prioritize developing medical treatments for emerging viral threats?
